Lausanne based Biotech company AC Immune has applied to list its common shares on the NASDAQ under the ticker symbol “ACIU.” AC Immune is the fourth Swiss Biotech company to go public this year.
AC Immune SA announced today that it has commenced the initial public offering of 4,545,456 of its common shares pursuant to a registration statement on Form F-1 with the U.S. Securities and Exchange Commission. In connection with the offering, AC Immune intends to grant the underwriters the option to purchase up to 681,818 additional common shares to cover over-allotments, if any. The estimated price range for the initial public offering is $11.00 to $13.00 per common share.
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins.
A registration statement on Form F-1 relating to the proposed offering has been filed with the SEC but has not yet become effective. The common shares to be registered may not be sold nor may offers to buy be accepted prior to the time when the registration statement becomes effective.
Startupticker reported about the filing in June. Two other Swiss biotech companies - Kuros and GeNeuro - already went public this year. A third company - ADIENNE - announced IPO plans this Monday. You can find all our news about IPOs using our tag "IPO"
Picture: Fotalia.com - Gary
(Press release)
Please login or sign up to comment.
Commenting guidelines